Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Talanta|October 11, 2015
A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelinesIris Garrido-Cano, Aurelio García-García, Juan Peris-Vicente, et al.
Cancer Metastasis Reviews|September 15, 2021
MicroRNAs as a clue to overcome breast cancer treatment resistanceIris Garrido-Cano, Birlipta Pattanayak, Anna Adam-Artigues, et al.
Frontiers in Oncology|April 1, 2022
Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression ProjectAmparo Belltall, Sheila Zúñiga-Trejos, Iris Garrido-Cano, et al.
ACS Sensors|February 18, 2021
Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic ToolIris Garrido-Cano, Luis Pla, Sara Santiago-Felipe, et al.
Frontiers in Oncology|April 25, 2022
Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control StudyAmparo Belltall, Guido Mazzinari, Iris Garrido-Cano, et al.
International Journal of Molecular Sciences|August 7, 2021
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical PerspectiveCristina Hernando, Belén Ortega-Morillo, Marta Tapia, et al.
ACS Applied Materials & Interfaces|August 7, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer TherapyIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
Cancers|September 28, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER TherapiesMarta Tapia, Cristina Hernando, María Teresa Martínez, et al.
International Journal of Molecular Sciences|February 25, 2023
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast CancerSandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, et al.
Molecular Medicine (Cambridge, Mass.)|March 26, 2025
Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancerAna Lameirinhas, Sandra Torres-Ruiz, Iris Garrido-Cano, et al.
Pageof 2